354 Results
Sort By:
Published on December 8, 2022
Black men suffer higher rates of prostate cancer, and now research points to genetic variants that may be responsible for early-onset prostate cancer among this population. Researchers at the Wayne State University School of Medicine and the Barbara Ann Karmanos Cancer Institute have found putative markers of the disease in…
Published on November 30, 2022
Research carried out at Wayne State and Duke University Schools of Medicine has identified 26 unique genetic variants in Black men that appear to be associated with more severe prostate cancer in this population group. Prostate cancer is the most common cancer diagnosed in adult men in the U.S. Although…
Published on August 24, 2022
UK researchers have shown that incorporating a genetic risk score (GRS) for prostate cancer into routine clinical care could help identify patients at greatest risk for the disease who should be prioritized for investigation. The risk score, developed by a team at the University of Exeter, could also help men…
Published on August 18, 2022
Calculating the genetic risk of men who visit primary care for suspected prostate cancer could lead to earlier diagnosis of the disease and avoid the need for invasive biopsies, U.K. research suggests. With the U.K. primary care physicians making around 800,000 prostate cancer referrals in the U.K. each year, incorporating…
Published on July 27, 2022
A population study involving more than 13,000 patients, has shown that hormone therapy for prostate cancer increases the risk of cardiovascular disease-related death especially in older men, according to a paper published Thursday in the journal Aging Male. The highest risk was for coronary heart disease and stroke. The increased…
Published on July 6, 2022
Men with prostate cancer have a distinct gut microbial profile to those with benign biopsies, which researchers say could partly explain the association between lifestyle factors and geographic differences in prostate cancer incidence. The findings were presented at the European Association of Urology (EAU) Annual Meeting in Amsterdam by Peter…
Published on June 22, 2022
Researchers at Moffitt Cancer Center report they have discovered a mechanism by which prostate cancer cells become resistant through molecular modification of the androgen receptor protein and identified a potential treatment approach that could overcome this resistance in mice. Their findings are published in the journal Science Translational Medicine in a paper…
Published on June 1, 2022
A newly identified, previously unknown subtype of hormone-resistant prostate cancer accounts for about 30% of all cases, according to a new study in Science from a team of scientists at Memorial Sloan Kettering Cancer Center (MSK) and Weill Cornell Medicine. The results could pave the way for targeted therapies for people…
Published on May 19, 2022
A team of Cleveland Clinic-led researchers have discovered how prostate cancer tumor cells evade therapy, and in the process have, have identified a promising new treatment strategy that can circumvent the drug resistance that often develops. Antiandrogen strategies are the backbone of prostate cancer treatments, but they are prone to…
Published on April 13, 2022
Incorporating genetic factors that influence prostate-specific antigen (PSA) level into prostate cancer screening may help reduce unnecessary invasive testing and improve the detection of aggressive disease, show data presented at the AACR 2022 annual meeting in New Orleans. Although PSA testing is widely used in prostate cancer diagnosis, population-based PSA…
Published on March 16, 2022
Androgen deprivation therapy for prostate cancer involves depriving the cancer cells of this fuel by either blocking the production or action of androgen hormones. Although hormone therapy plays an important role in treating patients with advancing prostate cancer, it is increasingly being used to treat localized disease as well. However,…
Published on March 15, 2022
Black men with prostate cancer may respond well to androgen deprivation therapy (ADT)-based regimens, but they are less likely to receive such therapy than non-Blacks, according to a new multi-institutional retrospective analysis. The study also found that black men with metastatic hormone-sensitive prostate cancer (mHSPC) are more likely to carry…
Published on February 22, 2022
Scientists at Massachusetts General Hospital (MGH) have demonstrated that adding the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy extends the survival of men with metastatic, hormone-sensitive prostate cancer, according to an international, randomized, double-blind, placebo-controlled, Phase III clinical trial. Their study is published in the New England Journal of Medicine in…
Published on February 9, 2022
While prostate cancer treatment options such as androgen deprivation therapy and chemotherapy are effective in early stages of the disease, once the disease progresses to metastatic castration-resistant prostate cancer (mCRPC), the prognosis is poor. More than 350,000 men die of prostate cancer every year. highlighting the need for new and…
Published on January 26, 2022
A study led by UCLA researchers has found that the optimal duration of androgen deprivation therapy (ADT) given to men with high-risk prostate cancer may vary according to the dose of radiotherapy they have received. The analysis, which combined individual patient data from three different cohorts, showed that men receiving…